التفاصيل البيبلوغرافية
| العنوان: |
The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non–small cell lung cancer. |
| المؤلفون: |
Kawahara, Akihiko, Azuma, Koichi, Hattori, Satoshi, Nakashima, Kazutaka, Basaki, Yuji, Akiba, Jun, Takamori, Sinzo, Aizawa, Hisamichi, Yanagawa, Takashi, Izumi, Hiroto, Kohno, Kimitoshi, Kono, Suminori, Kage, Masayoshi, Kuwano, Michihiko, Ono, Mayumi |
| المصدر: |
Human Pathology; Jul2010, Vol. 41 Issue 7, p951-959, 9p |
| مصطلحات موضوعية: |
LUNG cancer & genetics, GENETIC mutation, EPIDERMAL growth factor, ANTINEOPLASTIC agents, IMMUNOHISTOCHEMISTRY, GENE expression, DISEASE progression |
| مستخلص: |
Summary: Patients with non–small cell lung cancer harboring mutations in the epidermal growth factor receptor gene, including delE746-A750 and L858R, are highly sensitive to therapy with epidermal growth factor receptor–targeting drugs, such as gefitinib and erlotinib, in comparison with those harboring wild-type epidermal growth factor receptor. It remains unclear how such epidermal growth factor receptor mutations are induced. In this study, we examined whether 8-hydroxy-2′-deoxyguanosine, a representative oxygen nucleotide of DNA, could play a role in activating mutations of the epidermal growth factor receptor gene and also whether Y-box binding protein–1 and 8-oxoguanine DNA glycosylase that are involved in repair of oxidative stimuli-induced DNA damages could play any role in epidermal growth factor receptor activating mutations. Immunohistochemistry was used to evaluate the expression of 8-hydroxy-2′-deoxyguanosine, Y-box binding protein–1, and 8-oxoguanine DNA glycosylase in patients with non–small cell lung cancer (N = 170). We analyzed mutations of delE746-A750 and L858R in the epidermal growth factor receptor gene using peptide nucleic acid–locked nucleic acid polymerase chain reaction clamping. In non–small cell lung cancer patients, nuclear 8-hydroxy-2′-deoxyguanosine expression was strongly associated with these epidermal growth factor receptor mutations. Furthermore, nuclear expression of Y-box binding protein–1 was inversely associated with epidermal growth factor receptor mutations; but nuclear expression of 8-oxoguanine DNA glycosylase was not. Among 51 patients who were treated with gefitinib, progression-free survival was substantially better when 8-hydroxy-2′-deoxyguanosine expression was positive, when epidermal growth factor receptor mutations were present, and when nuclear Y-box binding protein–1 expression was negative. Thus, activating mutations of the epidermal growth factor receptor gene in non–small cell lung cancer were closely associated with a decrease in the damage repair process for 8-hydroxy-2′-deoxyguanosine in oxidized DNA. [Copyright &y& Elsevier] |
|
Copyright of Human Pathology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
